- Postdoc PhD
- +47 2278 1439
Link to UiO home page at the Institute of Clinical Medicine, UiO.
My research includes a basic immunology to understand the mechanisms of regulatory T cells (Treg) suppression of effector T cells (Teff). This knowledge can be extrapolated or translated into pathological settings such as cancer and autoimmune diseases.
My current projects include:
1. Understanding the molecular mechanisms of mutual interaction of Tregs and Teffs.
This project involves a comprehensive understanding of the mechanisms on how Tregs maintain immune homeostasis by regulating effector immune system.
2. Mechanisms of immune regulation by regulatory T cells in liver transplantation (Marie Curie Actions (FP7) EU co-fund project).
Here I will investigate the dual role of Tregs in controlling autoimmunity (Primary Sclerosing Cholangitis, PSC) versus a malignancy (Hepatocellular Carcinoma, HCC) and their role in the complex immunological interactions that take place before and after liver transplantation.
Previously I worked as a postdoc at the Department of Immunology, Indiana University School of Medicine, IN USA. where I was working on graft vs. host disease after hematopoietic stem cell transplantation. I graduated in 2015 from the University Medical Center Groningen, Groningen, the Netherlands. My PhD thesis was on Human Leukocyte Antigen and Classical Hodgkin Lymphoma. Earlier, I was working on Chikungunya virus infection at All India Institute of Medical Sciences, New Delhi, India. My Masters (M.Sc. Biotechnology) was from Bangalore University, Bangalore, KA India. I was born and bought up in Bangalore, KA India.
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Oncoimmunology, 6 (4), e1295202
JAK polymorphisms: jack of all cytokines, masters GVHD?
Leuk Lymphoma, 58 (2), 255-256
Biomarker Panel for Chronic Graft-Versus-Host Disease
J Clin Oncol, 34 (22), 2583-90
Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms
Cancer Epidemiol Biomarkers Prev, 23 (12), 2737-47
HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China
PLoS One, 7 (2), e31865
HLA associations in classical Hodgkin lymphoma: EBV status matters
PLoS One, 7 (7), e39986
Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups
Blood, 118 (19), 5211-7 (Retracted)